Page 5 - க்ரீஃப்ஸ்‌வால்ட் பல்கலைக்கழகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Wednesday, 21 April, 2021 - 17:00 Vials of Oxford AstraZeneca s COVID-19 vaccine are pictured at a vaccination center in Bierset, Belgium March 17, 2021. (Reuters) Asharq Al-Awsat European regulators said the benefits of using Johnson & Johnson s and AstraZeneca s COVID-19 vaccines outweigh risks, even as they added warning labels to both shots for extremely rare but potentially fatal blood clotting. J&J said on April 20 it would resume deliveries of its vaccine in Europe, following the regulator s guidance. US officials are continuing their review of what are now eight reported instances of rare clotting combined with low blood platelets in the United States. Britain s health regulator has recommended people under the age of 30 get an alternative COVID-19 vaccine, if possible, rather than the AstraZeneca shot, while some other European countries are only administering the shot to older people.

United statesUnited kingdomMecklenburg vorpommernGreifswald universityA us centers for diseaseUniversity of cambridge winton centre for riskRegulatory agencyEuropean unionEuropean medicines agencyDisease controlEuropean economic areaWinton centreஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்மெக்லென்பர்க் வோர்பொம்மேர்ன்க்ரீஃப்ஸ்‌வால்ட் பல்கலைக்கழகம்